Cargando…

BET bromodomain inhibition suppresses T(H)17-mediated pathology

Interleukin (IL) 17–producing T helper (T(H)17) cells have been selected through evolution for their ability to control fungal and bacterial infections. It is also firmly established that their aberrant generation and activation results in autoimmune conditions. Using a characterized potent and sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mele, Deanna A., Salmeron, Andres, Ghosh, Srimoyee, Huang, Hon-Ren, Bryant, Barbara M., Lora, Jose M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2013
Materias:	Brief Definitive Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804955/ https://www.ncbi.nlm.nih.gov/pubmed/24101376 http://dx.doi.org/10.1084/jem.20130376

Ejemplares similares

Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice
por: Sullivan, Josefa M., et al.
Publicado: (2015)

Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection
por: Milner, J. Justin, et al.
Publicado: (2021)

Distinct requirements for T-bet in gut innate lymphoid cells
por: Sciumé, Giuseppe, et al.
Publicado: (2012)

Requirement for T-bet in the aberrant differentiation of unhelped memory CD8(+) T cells
por: Intlekofer, Andrew M., et al.
Publicado: (2007)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Early T-bet promotes LFA1 upregulation required for CD8(+) effector and memory T cell development
por: Pritchard, Gretchen Harms, et al.
Publicado: (2022)

Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis
por: Cruz, Andrea, et al.
Publicado: (2010)

CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation
por: Ehirchiou, Driss, et al.
Publicado: (2007)

Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Resistance to Leishmania major is Linked to the H2 Region on Chromosome 17 and to Chromosome 9
por: Roberts, Lynden J., et al.
Publicado: (1997)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity
por: Klotz, Luisa, et al.
Publicado: (2009)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains
por: Nakagawa, Akifumi, et al.
Publicado: (2016)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

A specific role for TLR1 in protective T(H)17 immunity during mucosal infection
por: DePaolo, R. William, et al.
Publicado: (2012)

The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells
por: Kim, Jiyeon S., et al.
Publicado: (2011)

COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation
por: Ghosh, Mallika, et al.
Publicado: (2007)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides
por: Liang, Spencer C., et al.
Publicado: (2006)

BET Bromodomain Inhibitors Suppress Inflammatory Activation of Gingival Fibroblasts and Epithelial Cells From Periodontitis Patients
por: Maksylewicz, Anna, et al.
Publicado: (2019)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
por: Dutra, Luiz Antonio, et al.
Publicado: (2017)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of T(H)17 and T(reg) cells
por: Shi, Lewis Z., et al.
Publicado: (2011)

Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state T(H)17 cells in the intestine
por: Shaw, Michael H., et al.
Publicado: (2012)

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I
por: Puel, Anne, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_86i3fo93hdrnrp27j6849fr8c9